Cancer drugs: Is Astra Zeneca cashing in on patients desperation

Cancer drugs: Is AstraZeneca cashing in on patients desperation Big Pharma s business model is fraud: it has turned oncology into a multibillion business, while its drugs are often minimally effective, argues Dr. Paul Marik. Do his concerns have merit British pharma giant AstraZeneca claims to have a boldambition toprovide cures for cancer inevery form with a broad pipeline of nextgeneration medicines In Q2, AstraZeneca s revenue rose 12 to with cancer drug sales accounting for 40+ of total revenue In 2024, AstraZeneca generated in revenue from oncology, accounting for 41 of its total revenue of Too expensive, not so effective In May 2024, the Drug Controller General of India (DCGI) directed the nation s regulators to withdraw AstraZenecas cancer drug Olaparib due to adverse effects In June 2024, AstraZeneca admitted that its breast cancer drug Truqap failed to improve overall survival in patients In September 2024, the overall Source: Geopolitics Prime t. me, geopoliticsprime